(HealthDay News) — For patients with renal cell carcinoma (RCC), preoperative serum cholesterol is an independent prognostic factor, according to a study published online June 12 in BJU International.
Michela de Martino, PhD, from the Medical University of Vienna, and colleagues examined the prognostic role of preoperative serum cholesterol in patients with RCC. Data were obtained from 867 patients with RCC who underwent radical or partial nephrectomy between 2002 and 2011. Participants were followed for a median period of 52 months.
The researchers found that decreasing serum cholesterol correlated with more advanced T, N, and M stages, higher grades, and presence of tumor necrosis (P<0.001, P=0.001, and P=0.002, respectively).
In univariate and multivariable analyses, continuously coded cholesterol correlated with cancer-specific survival (hazard ratios, 0.87 [P<0.001] and 0.93 [P=0.001], respectively). Following inclusion of cholesterol, there was a significant increase in the discrimination of a multivariable base model, from 88.3% to 89.2% (P=0.006).
Cholesterol remained associated with cancer-specific survival in patients with clinically localized disease (T1-3N0/+M0) in multivariable analysis (hazard ratio, 0.90; P=0.002) and increased the model discrimination from 74.6% to 76.9% (P=0.002).
“Preoperative serum cholesterol is an independent prognostic factor for patients with RCC, with lower levels being associated with worse survival,” the researchers wrote.